Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage

20051,164 citationsJournal Articlebronze Open Access

Authors

Stephan A. Mayer · Columbia University

Nikolai C. Brun · Novo Nordisk (Denmark)

Kamilla Begtrup · Novo Nordisk (Denmark)

Joseph Broderick · University of Cincinnati

Stephen M. Davis · University of Melbourne

Michael N. Diringer · Washington University in St. Louis

Brett E. Skolnick

Abstract

Treatment with rFVIIa within four hours after the onset of intracerebral hemorrhage limits the growth of the hematoma, reduces mortality, and improves functional outcomes at 90 days, despite a small increase in the frequency of thromboembolic adverse events.

Topics & Keywords

Intracerebral and Subarachnoid Hemorrhage Research Hemophilia Treatment and Research Spinal Hematomas and Complications

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 352, Issue 8, pp. 777-785

DOI: 10.1056/nejmoa042991

Field-Weighted Citation Impact: 99.04